Skip to content
Biodatica
Start free

Investigator

Hui-Kuan Lin

DUKE UNIVERSITY · funded by NCI

Companies
1

Resolved onto their grants.

Grants
5

Federal awards on file.

Non-dilutive funding
$2.7M

Summed across those awards.

First award
Jan 3, 2022

Latest Jun 9, 2026.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R01

    Identification and inhibition of the novel downstream effectors of mutant Ras for mutant Ras-driven cancer targeting

    $693k

    Jun 9, 2026NCIDUKE UNIVERSITYNIH RePORTER · 11363259 (opens the source filing in a new tab)

  2. R01

    Regulation of oncogenic Akt ubiquitination and activation by diverse mechanisms in cancer

    $468k

    Jul 1, 2023NCIDUKE UNIVERSITYNIH RePORTER · 11141128 (opens the source filing in a new tab)

  3. R01

    Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer

    $513k

    Feb 9, 2023NCIDUKE UNIVERSITYNIH RePORTER · 11030328 (opens the source filing in a new tab)

  4. R01

    Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer

    $507k

    Feb 9, 2023NCIDUKE UNIVERSITYNIH RePORTER · 11258495 (opens the source filing in a new tab)

  5. R01

    Unravel a novel metabolic pathway orchestrating prostate cancer progression and therapeutic resistance

    $521k

    Jan 3, 2022NCIDUKE UNIVERSITYNIH RePORTER · 11169667 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources